Stanley Druckenmiller Tg Therapeutics, Inc. Transaction History
Duquesne Family Office LLC
- $2.95 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding TGTX
# of Institutions
338Shares Held
88.3MCall Options Held
2.35MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA15.4MShares$455 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$336 Million0.0% of portfolio
-
State Street Corp Boston, MA9.09MShares$269 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.58MShares$106 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA3.21MShares$94.7 Million0.01% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.29B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...